Side Effects Dana White Publicly Discussed (and What They Match in the Clinical Literature)

What Dana White Has Said on the Record

Dana White spoke openly about health interventions during interviews in 2023 and 2024, a period that followed a widely covered confrontation with his wife on New Year's Eve 2022 and subsequent public statements about prioritizing his health. In multiple podcast appearances, White described working with physicians, using testosterone, and adopting an aggressive approach to body recomposition.

In a January 2024 appearance on the Full Send Podcast, White discussed receiving hormone-related treatments and credited them, along with dietary changes, for a rapid shift in body composition. He has also referenced Gary Brecka, a self-described human biologist, as someone who influenced his health protocols.

White's exact testosterone formulation, dose, and administration route have not been publicly confirmed. He has mentioned "testosterone" in general terms without specifying whether he uses injectable testosterone cypionate, enanthate, topical gel, or another preparation. The HealthRX.com Medical Team treats all specific protocol details as speculated unless White or his prescribing physician disclose them directly.

The Reported Physical Changes

Between mid-2023 and early 2024, mainstream media outlets documented visible changes in White's physique. He appeared leaner with reduced facial fullness and increased vascularity, changes consistent with the body-composition effects of exogenous testosterone combined with caloric restriction.

White himself described rapid weight loss and improved energy levels. He has publicly attributed these changes to a combination of testosterone therapy, dietary overhaul (including a 10-day water fast he discussed on social media), and peptide-related interventions.

These self-reported effects align with the known pharmacology of testosterone. A 2016 meta-analysis in The Journal of Clinical Endocrinology & Metabolism confirmed that testosterone therapy in men with low baseline levels produces statistically significant reductions in fat mass (mean reduction of 1.6 kg) and increases in lean mass (mean increase of 1.6 kg) over trial durations averaging 34 weeks.

Clinical Side-Effect Profile: What the FDA Label Documents

The FDA-approved prescribing information for testosterone cypionate lists the following adverse events. White has publicly discussed some of these. Others are included because any patient on TRT should be monitored for them.

Cardiovascular effects. The FDA added a black-box warning update in 2015 regarding possible increased risk of heart attack and stroke with testosterone products. The 2023 TRAVERSE trial, published in The New England Journal of Medicine, followed 5,246 men for a mean of 33 months and found that testosterone did not significantly increase the incidence of major adverse cardiovascular events compared to placebo (7.0% vs. 7.3%; hazard ratio 0.96). White has not publicly reported any cardiovascular symptoms.

Polycythemia (elevated red blood cells). Testosterone stimulates erythropoiesis. The TRAVERSE trial reported polycythemia in 4.2% of men receiving testosterone versus 1.2% on placebo. This is one of the most common laboratory abnormalities requiring monitoring. White has not publicly discussed hematocrit levels, though any prescribing physician managing his TRT would be expected to track this with routine bloodwork.

Acne and skin changes. Testosterone increases sebum production. The FDA label lists acne as a common adverse reaction, and the Endocrine Society's 2018 clinical practice guideline recommends monitoring for dermatologic changes. White has not specifically addressed acne in public statements.

Sleep disturbances. Exogenous testosterone can worsen or trigger obstructive sleep apnea (OSA). The Endocrine Society guideline lists untreated severe OSA as a relative contraindication to TRT initiation. White discussed sleep quality improvements after beginning his health overhaul, though he attributed those changes broadly to lifestyle modifications rather than to testosterone specifically.

Mood and behavioral effects. Supraphysiologic testosterone doses are associated with irritability and mood lability. At replacement doses (targeting mid-normal range, typically 400 to 700 ng/dL), clinical trials show either neutral or mildly positive effects on mood. A 2019 systematic review in JAMA Internal Medicine found modest improvements in depressive symptoms among hypogonadal men receiving replacement-dose testosterone. White has described feeling "better than ever" but has not publicly linked mood changes to testosterone in isolation.

Hepatic effects. Oral 17-alpha-alkylated androgens carry hepatotoxicity risk, but injectable testosterone esters (cypionate, enanthate) and topical formulations are not associated with significant liver toxicity at standard doses. This distinction matters because White has not disclosed his route of administration. If he uses an injectable or topical preparation, as is standard clinical practice for TRT, liver toxicity risk is minimal.

What White Has Not Addressed Publicly

Several clinically important monitoring parameters have gone unmentioned in White's public statements. That does not mean they are being ignored by his physicians; it means the public record is incomplete.

• PSA and prostate screening. The Endocrine Society recommends PSA measurement at baseline, 3 to 6 months, and then annually. White has not discussed prostate monitoring.
• Bone mineral density. While testosterone supports bone health, this is typically relevant for men with documented osteoporosis or prolonged hypogonadism. No public statements from White address this.
• Fertility and testicular volume. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing or eliminating spermatogenesis. A 2006 study in The Lancet demonstrated azoospermia in approximately 65% of men receiving testosterone as a contraceptive. At 56, White may consider this clinically irrelevant, but the suppression of endogenous production remains a physiologic effect worth noting.

Why the UFC President's Public Posture Matters

White runs the organization that banned TRT therapeutic-use exemptions (TUEs) in combat sport in 2014. Before that ban, fighters like Vitor Belfort, Chael Sonnen, and Dan Henderson competed under TRT exemptions, a practice White himself criticized publicly at the time.

His own disclosed use of testosterone, outside of competition, is a different clinical scenario. A 56-year-old executive managing age-related hypogonadal symptoms is not the same as a 30-year-old athlete seeking performance advantage. The pharmacology is identical, but the clinical intent, dosing targets, and ethical framing differ entirely.

The HealthRX.com Medical Team notes that White's willingness to discuss TRT publicly, even in general terms, has brought visibility to a therapy that roughly 2.3 million American men were prescribed as of 2013, a figure that has grown since. His platform matters because the combat-sport audience skews toward men aged 18 to 44, exactly the demographic most likely to encounter testosterone marketing and least likely to understand the difference between replacement and supraphysiologic dosing.

At a glance

• Dana White has publicly confirmed using testosterone as part of a broader health protocol starting around 2023.
• Specific formulation, dose, and administration route remain publicly unconfirmed.
• His reported effects (fat loss, increased energy, improved body composition) are consistent with the clinical trial literature on TRT in hypogonadal men.
• Common TRT side effects include polycythemia, acne, sleep apnea exacerbation, and HPG axis suppression.
• The 2023 TRAVERSE trial found no significant increase in major cardiovascular events with testosterone replacement over 33 months.
• Monitoring requirements include hematocrit, PSA, lipid panel, and liver function tests per Endocrine Society guidelines.

Frequently asked questions

›

›

›

›

›

References

• Corona G, et al. "Testosterone supplementation and body composition: results from a meta-analysis of observational studies." J Endocrinol Invest. 2016. PubMed
• Lincoff AM, et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." N Engl J Med. 2023. NEJM
• Bhasin S, et al. "Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2018. PubMed
• Snyder PJ, et al. "Lessons from the Testosterone Trials." Endocr Rev. 2018. PubMed
• FDA Drug Safety Communication: Testosterone Products. 2015. FDA
• Gu Y, et al. "A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men." Lancet. 2006. Lancet
• Baillargeon J, et al. "Trends in androgen prescribing in the United States, 2001 to 2011." JAMA Intern Med. 2013. PubMed
• Walther A, et al. "Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men." JAMA Psychiatry. 2019. JAMA